In this Forbes feature, Dr. Nathan S. Bryan, a leading biochemist and pioneer in nitric oxide research, discusses how artificial intelligence is reshaping biotechnology. He explains how AI can shorten the 17-year gap between discovery and drug development by automating data analysis, mapping proteins, and improving diagnostics.
Dr. Bryan highlights breakthroughs such as DeepMind’s AI-generated protein map and the rise of open-source AI platforms that streamline lab work and accelerate innovation. He describes how AI supports nitric oxide research—monitoring vital signs, analyzing safety data, and identifying early signs of chronic disease.
According to Bryan, the future of biotechnology lies in AI-driven precision: using real-time data to predict disease, personalize treatment, and create safe, effective therapeutics faster than ever before. He concludes that if handled responsibly, AI could be the catalyst for a new era of medical discovery and global health advancement.
👉 Read the full Forbes article for Dr. Bryan’s complete insights on AI and biotechnology.